Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy

被引：0
作者：
Anna Rydén
Fiona Blackhall
Hye Ryun Kim
Rathi N. Pillai
Lauren Braam
Mona L. Martin
Andrew Walding
机构：
[1] AstraZeneca Gothenburg,Division of Molecular and Clinical Cancer Sciences
[2] University of Manchester,Department of Medical Oncology, Yonsei Cancer Center
[3] The Christie NHS Foundation Trust,Department of Hematology and Medical Oncology, School of Medicine
[4] Yonsei University College of Medicine,undefined
[5] Winship Cancer Institute of Emory University,undefined
[6] Health Research Associates Inc.,undefined
[7] AstraZeneca R&D,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2017年 / 10卷
关键词：
Epidermal Growth Factor Receptor; Initial Interview; Poor Appetite; Bothersome Symptom; Transcript Database;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：593 / 603
页数：10
相关论文
共 50 条
  • [1] Necitumumab for the treatment of advanced non-small-cell lung cancer
    Diaz-Serrano, Asuncion
    Sanchez-Torre, Ana
    Paz-Ares, Luis
    [J]. FUTURE ONCOLOGY, 2019, 15 (07) : 705 - 716
  • [2] The Emerging Role of Biomarkers in Advanced Non-Small-Cell Lung Cancer
    Socinski, Mark A.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (03) : 149 - 159
  • [3] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
    Lee, Jin Hwa
    Lee, Kyoung Eun
    Ryu, Yon Ju
    Chun, Eun Mi
    Chang, Jung Hyun
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
  • [4] Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report
    Yang, Zhengyuan
    Lin, Yingcheng
    Wang, Hongbiao
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (08)
  • [5] CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Park, Sun Hoo
    Park, Jong Heon
    Lee, Jae Cheol
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 247 - 253
  • [6] Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer
    Gandara, David R.
    Riess, Jonathan W.
    Kelly, Karen
    Li, Tianhong
    Mack, Philip C.
    Lara, Primo N., Jr.
    [J]. CLINICAL LUNG CANCER, 2017, 18 (01) : 1 - 4
  • [7] GefitinibA Review of its Use in the Management of Advanced Non-Small-Cell Lung Cancer
    James E. Frampton
    Stephanie E. Easthope
    [J]. Drugs, 2004, 64 : 2475 - 2492
  • [8] A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib
    Donovan, Michael J.
    Kotsianti, Angeliki
    Bayer-Zubek, Valentina
    Verbel, David
    Teverovskiy, Mikhail
    Cordon-Cardo, Carlos
    Costa, Jose
    Greco, F. Anthony
    Hainsworth, John D.
    Parums, Dinah V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1518 - 1526
  • [9] Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan
    Hiroki Nagai
    Shiro Tanaka
    Miyuki Niimi
    Nanae Seo
    Takahiko Sasaki
    Hiroshi Date
    Michiaki Mishima
    Hiroyasu Yasuda
    Kazuhiro Yanagihara
    [J]. International Journal of Clinical Oncology, 2011, 16
  • [10] Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer
    Perez Carrion, Ramon
    Cubillo Gracian, Antonio
    Salinas Hernandez, Pedro
    [J]. CLINICAL LUNG CANCER, 2007, 8 (07) : 425 - 428
12345